3-52405163-G-A
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_004656.4(BAP1):c.1063C>T(p.Gln355*) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. Q355Q) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_004656.4 stop_gained
Scores
Clinical Significance
Conservation
Publications
- BAP1-related tumor predisposition syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Ambry Genetics, G2P, Orphanet, Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
- Kury-Isidor syndromeInheritance: AD Classification: STRONG, MODERATE Submitted by: Ambry Genetics, G2P
- renal cell carcinomaInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_004656.4. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| BAP1 | NM_004656.4 | MANE Select | c.1063C>T | p.Gln355* | stop_gained | Exon 11 of 17 | NP_004647.1 | ||
| BAP1 | NM_001410772.1 | c.1009C>T | p.Gln337* | stop_gained | Exon 11 of 17 | NP_001397701.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| BAP1 | ENST00000460680.6 | TSL:1 MANE Select | c.1063C>T | p.Gln355* | stop_gained | Exon 11 of 17 | ENSP00000417132.1 | ||
| BAP1 | ENST00000296288.9 | TSL:5 | c.1009C>T | p.Gln337* | stop_gained | Exon 11 of 17 | ENSP00000296288.5 | ||
| BAP1 | ENST00000490804.1 | TSL:2 | n.491C>T | non_coding_transcript_exon | Exon 1 of 3 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:2
The p.Q355* pathogenic mutation (also known as c.1063C>T), located in coding exon 11 of the BAP1 gene, results from a C to T substitution at nucleotide position 1063. This changes the amino acid from a glutamine to a stop codon within coding exon 11. This mutation was observed in a patient with a history of melanoma and kidney cancer who underwent multi-gene panel testing (Shirts BH et al. Genet. Med., 2016 Oct;18:974-81). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
BAP1-related tumor predisposition syndrome Pathogenic:1
This sequence change creates a premature translational stop signal (p.Gln355*) in the BAP1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BAP1 are known to be pathogenic (PMID: 21874000, 23684012). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with melanoma and kidney cancer (PMID: 26845104). ClinVar contains an entry for this variant (Variation ID: 224520). Studies have shown that this premature translational stop signal is associated with inconclusive levels of altered splicing (Invitae). For these reasons, this variant has been classified as Pathogenic.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at